Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis

BackgroundPostoperative nausea and vomiting (PONV) remains a challenge for patients and health professionals despite various newly developed prophylactic interventions. We reviewed the efficacy and safety of ramosetron in randomized controlled trials (RCTs) for the prevention of PONV.MethodsWe revie...

Full description

Bibliographic Details
Main Authors: Won Oak Kim, Bon Nyeo Koo, Yong Kook Kim, Hae Keum Kil
Format: Article
Language:English
Published: Korean Society of Anesthesiologists 2011-11-01
Series:Korean Journal of Anesthesiology
Subjects:
Online Access:http://ekja.org/upload/pdf/kjae-61-405.pdf
_version_ 1818341496139546624
author Won Oak Kim
Bon Nyeo Koo
Yong Kook Kim
Hae Keum Kil
author_facet Won Oak Kim
Bon Nyeo Koo
Yong Kook Kim
Hae Keum Kil
author_sort Won Oak Kim
collection DOAJ
description BackgroundPostoperative nausea and vomiting (PONV) remains a challenge for patients and health professionals despite various newly developed prophylactic interventions. We reviewed the efficacy and safety of ramosetron in randomized controlled trials (RCTs) for the prevention of PONV.MethodsWe reviewed 18 randomized controlled trials investigating the efficacy and safety of ramosetron in comparison with placebo or any other drugs. Relevant studies were searched in the MEDLINE, SCOPUS, and the Cochrane database libraries. Our end points of concern were prevention of PONV and adverse effects as dichotomous data.ResultsThe prophylactic effect of 0.3 mg ramosetron was observed in early PON (relative risk, RR: 0.4; 95% CI 0.3-0.6), early POV (RR: 0.3; 95% CI 0.1-0.6), late POV (RR: 0.3; 95% CI 0.1-0.6), but not late PON (RR: 0.7; 95% CI 0.5-1.0). Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 µg/kg in children were consistently beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). The effects of 0.3 mg ramosetron and 3 mg granisetron were similar. No serious side effects or adverse events resulted from ramosetron and other active drugs, and incidence was similar to those of the placebo group.ConclusionsRamosetron is effective and safe in children and adults without serious adverse effects compared with placebo or other active drugs, as shown in pooled data of RCTs, in terms of the prevention of PONV.
first_indexed 2024-12-13T15:59:43Z
format Article
id doaj.art-9c1af5192dd4456a8ea0b2ddede3fff3
institution Directory Open Access Journal
issn 2005-6419
2005-7563
language English
last_indexed 2024-12-13T15:59:43Z
publishDate 2011-11-01
publisher Korean Society of Anesthesiologists
record_format Article
series Korean Journal of Anesthesiology
spelling doaj.art-9c1af5192dd4456a8ea0b2ddede3fff32022-12-21T23:39:13ZengKorean Society of AnesthesiologistsKorean Journal of Anesthesiology2005-64192005-75632011-11-0161540541210.4097/kjae.2011.61.5.4057224Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysisWon Oak Kim0Bon Nyeo Koo1Yong Kook Kim2Hae Keum Kil3Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine, Seoul, Korea.BackgroundPostoperative nausea and vomiting (PONV) remains a challenge for patients and health professionals despite various newly developed prophylactic interventions. We reviewed the efficacy and safety of ramosetron in randomized controlled trials (RCTs) for the prevention of PONV.MethodsWe reviewed 18 randomized controlled trials investigating the efficacy and safety of ramosetron in comparison with placebo or any other drugs. Relevant studies were searched in the MEDLINE, SCOPUS, and the Cochrane database libraries. Our end points of concern were prevention of PONV and adverse effects as dichotomous data.ResultsThe prophylactic effect of 0.3 mg ramosetron was observed in early PON (relative risk, RR: 0.4; 95% CI 0.3-0.6), early POV (RR: 0.3; 95% CI 0.1-0.6), late POV (RR: 0.3; 95% CI 0.1-0.6), but not late PON (RR: 0.7; 95% CI 0.5-1.0). Compared with placebo, the efficacy of 0.3 mg ramosetron in adults and 6 µg/kg in children were consistently beneficial in preventing PONV overall (RR: 0.4; 95% CI: 03-0.6). The effects of 0.3 mg ramosetron and 3 mg granisetron were similar. No serious side effects or adverse events resulted from ramosetron and other active drugs, and incidence was similar to those of the placebo group.ConclusionsRamosetron is effective and safe in children and adults without serious adverse effects compared with placebo or other active drugs, as shown in pooled data of RCTs, in terms of the prevention of PONV.http://ekja.org/upload/pdf/kjae-61-405.pdfantiemeticsmeta-analysisponvramosetron
spellingShingle Won Oak Kim
Bon Nyeo Koo
Yong Kook Kim
Hae Keum Kil
Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
Korean Journal of Anesthesiology
antiemetics
meta-analysis
ponv
ramosetron
title Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
title_full Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
title_fullStr Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
title_full_unstemmed Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
title_short Ramosetron for the prevention of postoperative nausea and vomiting (PONV): a meta-analysis
title_sort ramosetron for the prevention of postoperative nausea and vomiting ponv a meta analysis
topic antiemetics
meta-analysis
ponv
ramosetron
url http://ekja.org/upload/pdf/kjae-61-405.pdf
work_keys_str_mv AT wonoakkim ramosetronforthepreventionofpostoperativenauseaandvomitingponvametaanalysis
AT bonnyeokoo ramosetronforthepreventionofpostoperativenauseaandvomitingponvametaanalysis
AT yongkookkim ramosetronforthepreventionofpostoperativenauseaandvomitingponvametaanalysis
AT haekeumkil ramosetronforthepreventionofpostoperativenauseaandvomitingponvametaanalysis